SS-31 for Cardiac Health
Research, mechanism, dosing, and effectiveness of SS-31 for cardiac health.
Quick Answer
SS-31 is being studied for heart failure and mitochondrial cardiomyopathy.
Evidence Level
FDA Approved
Typical Dose
Clinical trial doses
Results Timeline
Cardiac benefits over weeks in trials
FDA Status
FDA Approved
How SS-31 Works for Cardiac Health
Improves cardiac mitochondrial function and ATP production.
About Cardiac Health
Support for heart function and cardiovascular health.
Research Evidence
FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency.
Dosing for Cardiac Health
Recommended Dose
Clinical trial doses
Frequency
Once daily
Administration
Subcutaneous injection or IV infusion
Duration
Variable by condition
Note: FDA approved as FORZINITY for Barth syndrome. Subcutaneous injection for patients weighing at least 30 kg.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (very common - 80%)
- •Headache
- •Dizziness
- •Nausea
- •May trigger histamine release - use caution with MCAS or histamine sensitivity
- •No serious adverse events in trials
Frequently Asked Questions
Does SS-31 help with cardiac health?
SS-31 is being studied for heart failure and mitochondrial cardiomyopathy.
How does SS-31 work for cardiac health?
Improves cardiac mitochondrial function and ATP production....
What dose of SS-31 should I use for cardiac health?
Clinical trial doses
How long until I see results?
Cardiac benefits over weeks in trials
Other Peptides for Cardiac Health
These peptides are also researched for cardiac health.
NAD+ Precursors
Clinical TrialsWhile not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
FOXO4-DRI
PreclinicalA senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging, including kidney health restoration.
Glutathione
Clinical TrialsThe body's master antioxidant - a tripeptide composed of glutamate, cysteine, and glycine. Found in every cell at concentrations similar to glucose (5mM). Essential for detoxification, immune function, and cellular protection against oxidative stress.
DSIP
Clinical TrialsA neuropeptide that promotes deep delta wave sleep. First isolated from rabbit brains in 1977. Used for sleep optimization and stress reduction.
Educational Information Only
This information about SS-31 for cardiac health is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.